Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial-Reference-Cited by-同舟云学术

Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial

Published:2019-09 Issue:1 Volume:1 Page:e44-e54
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Humrich Jens Y,von Spee-Mayer Caroline,Siegert Elise,Bertolo Martina,Rose Angelika,Abdirama Dimas,Enghard Philipp,Stuhlmüller Bruno,Sawitzki Birgit,Huscher Dörte,Hiepe Falk,Alexander Tobias,Feist Eugen,Radbruch Andreas,Burmester Gerd-Rüdiger,Riemekasten Gabriela

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference24 articles.

1. New insights into the immunopathogenesis of systemic lupus erythematosus;Tsokos;Nat Rev Rheumatol,2016

2. Beyond pan-B-cell-directed therapy—new avenues and insights into the pathogenesis of SLE;Dorner;Nat Rev Rheumatol,2016

3. FOXP3+ regulatory T cells in the human immune system;Sakaguchi;Nat Rev Immunol,2010

4. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization;Setoguchi;J Exp Med,2005

5. A function for interleukin 2 in Foxp3-expressing regulatory T cells;Fontenot;Nat Immunol,2005

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Directed disruption of IL2 aggregation sites produces designer biologics with enhanced specificity coupled to improved production capacity;2024-09-03

2. Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics;Immunity;2024-09

3. Psoriasis and Lupus Erythematosus—Similarities and Differences between Two Autoimmune Diseases;Journal of Clinical Medicine;2024-07-25

4. Current cell therapies for systemic lupus erythematosus;Stem Cells Translational Medicine;2024-06-26

5. Comparison of Low-Dose Interleukin 2 Therapy in Conjunction With Standard Therapy in Patients With Systemic Lupus Erythematosus vs Rheumatoid Arthritis: A Systematic Review;Cureus;2024-03-22